Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

trastuzumab rezetecan (SHR-A1811)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma

Drug class:

Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate

Related drugs:

‹

fam-trastuzumab deruxtecan-nxki (90)

irinotecan (48)

sacituzumab govitecan-hziy (17)

HRA00129-C004 (3)

nanoliposomal irinotecan (3)

camptothecin nanosomal (1)

HA-irinotecan (0)

ICAM‑1 ADC (0)

etirinotecan pegol (0)

irinotecan liposomal (0)

topotecan episcleral (0)

ado-trastuzumab emtansine (97)

disitamab vedotin (27)

trastuzumab duocarmazine (6)

PF-06804103 (4)

MF-TTZ-MMAE (1)

›

HER-2 mutation	Non Small Cell Lung Cancer	HER-2 mutation	Non Small Cell Lung Cancer	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 expression	Gastroesophageal Junction Adenocarcinoma	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 mutation	Gastric Cancer	HER-2 mutation	Gastric Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	HER-2 mutation	Gastroesophageal Junction Adenocarcinoma	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 mutation	Urothelial Cancer	HER-2 mutation	Urothelial Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 mutation	Biliary Tract Cancer	HER-2 mutation	Biliary Tract Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 mutation	Colorectal Cancer	HER-2 mutation	Colorectal Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 expression	Colorectal Cancer	HER-2 expression	Colorectal Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 expression	Biliary Tract Cancer	HER-2 expression	Biliary Tract Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3
HER-2 expression	Urothelial Cancer	HER-2 expression	Urothelial Cancer	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3	SHR-A1811 Sensitive: C3 – Early Trials SHR-A1811 Sensitive : C3